Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST-CR: Personalized Tumor FAST Vaccine Combined with Radiotherapy and Standard Treatment
ChiCTR2600128097Phase 2Not yet recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of FAST personalized tumor vaccine in Non-hematologic malignancy and cancer (3 arms), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoints: Incidence and Severity of Adverse Events at 12 months, Dose-Limiting Toxicity (DLT) at 12 months and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
FAST personalized tumor vaccine
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on ChiCTR2600128097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128097.